Treatment of Haemophilus influenzae Pneumonia in Outpatient Adults with Chronic Comorbidities
This protocol applies to adults presenting with community-acquired pneumonia managed entirely in the outpatient setting who have one or more significant comorbid conditions. The presence of these comorbidities directly shapes antibiotic selection.
Applicable comorbidities
Chronic heart disease
Chronic lung disease
Chronic liver disease
Chronic renal disease
Diabetes mellitus
Alcoholism
Malignancy
Asplenia
Clinical treatment goals
The target is achievement of clinical stability — resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. This is expected within 48 to 72 hours for most patients.
Treatment approach
Recommended antibiotic therapy for this population involves either combination therapy — pairing a beta-lactam agent with a complementary agent — or monotherapy with a respiratory fluoroquinolone.
The full regimen options, sequencing, and duration guidance are available in the structured protocol below.
References
DOI: 10.1164/rccm.201908-1581ST
- For outpatient adults with comorbidities such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia we recommend (in no particular order of preference) (Table 3):
- Combination therapy: a beta-lactam AND a macrolide (strong recommendation, moderate quality of evidence for combination therapy), or doxycycline (conditional recommendation, low quality of evidence for combination therapy); OR a respiratory fluoroquinolone (strong recommendation, moderate quality of evidence).
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗